{"id":182968,"date":"2025-10-14T18:42:42","date_gmt":"2025-10-14T18:42:42","guid":{"rendered":"https:\/\/dailytalks.org\/?p=182968"},"modified":"2025-10-14T18:42:42","modified_gmt":"2025-10-14T18:42:42","slug":"nmpa-accepted-essexs-biologics-license-application-for-eb12-20145p-hlx04-o-for-the-treatment-of-wet-age-related-macular-degeneration","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=182968","title":{"rendered":"NMPA Accepted Essex&#8217;s Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration"},"content":{"rendered":"<p>HONG KONG, Aug 13, 2025 &#8211; (ACN Newswire) &#8211;\u00a0Essex Bio-Technology Limited (\u201cEssex\u201d or the \u201cGroup\u201d, Stock Code: 1061.HK) is pleased to announce that a Biologics License Application (\u201cBLA\u201d) for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal antibody injection, has recently been accepted by the Centre for Drug Evaluation (\u201cCDE\u201d) of the National Medical Products Administration (\u201cNMPA\u201d) in China&#8230;<br \/><a href=\"https:\/\/en.acnnewswire.com\/press-release\/english\/101884\/\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HONG KONG, Aug 13, 2025 &#8211; (ACN Newswire) &#8211;\u00a0Essex Bio-Technology Limited (\u201cEssex\u201d or the \u201cGroup\u201d,<\/p>\n","protected":false},"author":1,"featured_media":182969,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[],"class_list":["post-182968","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/10\/182968-nmpa-accepted-essexs-biologics-license-application-for-eb12-20145p-hlx04-o-for-the-treatme68ee99a5086dc.jpg",220,67,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/10\/182968-nmpa-accepted-essexs-biologics-license-application-for-eb12-20145p-hlx04-o-for-the-treatme68ee99a5086dc-150x67.jpg",150,67,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/10\/182968-nmpa-accepted-essexs-biologics-license-application-for-eb12-20145p-hlx04-o-for-the-treatme68ee99a5086dc.jpg",220,67,false],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/10\/182968-nmpa-accepted-essexs-biologics-license-application-for-eb12-20145p-hlx04-o-for-the-treatme68ee99a5086dc.jpg",220,67,false],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/10\/182968-nmpa-accepted-essexs-biologics-license-application-for-eb12-20145p-hlx04-o-for-the-treatme68ee99a5086dc.jpg",220,67,false],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/10\/182968-nmpa-accepted-essexs-biologics-license-application-for-eb12-20145p-hlx04-o-for-the-treatme68ee99a5086dc.jpg",220,67,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/10\/182968-nmpa-accepted-essexs-biologics-license-application-for-eb12-20145p-hlx04-o-for-the-treatme68ee99a5086dc.jpg",220,67,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/10\/182968-nmpa-accepted-essexs-biologics-license-application-for-eb12-20145p-hlx04-o-for-the-treatme68ee99a5086dc.jpg",220,67,false],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/10\/182968-nmpa-accepted-essexs-biologics-license-application-for-eb12-20145p-hlx04-o-for-the-treatme68ee99a5086dc.jpg",220,67,false],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/10\/182968-nmpa-accepted-essexs-biologics-license-application-for-eb12-20145p-hlx04-o-for-the-treatme68ee99a5086dc.jpg",220,67,false]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=35\" rel=\"category\">Tech<\/a>","tag_info":"Tech","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/182968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=182968"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/182968\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/182969"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=182968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=182968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=182968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}